USCAREPHARM Co., Ltd., Suwon 16690, Republic of Korea.
Department of Biology Education, Teachers College and Institute for Phylogenomics and Evolution, Kyungpook National University, Daegu 41566, Republic of Korea.
Nutrients. 2024 Sep 20;16(18):3189. doi: 10.3390/nu16183189.
This study investigates the hypolipidemic effects of a mixed extract of and (USCP119) in HFD-fed hamsters and in vitro cellular models.
Over an 8-week period, HFD-fed hamsters were assigned to one of six groups: normal diet, HFD control, HFD with 50 mg/kg USCP119, HFD with 100 mg/kg USCP119, HFD with 50 mg/kg USCP119 twice daily (BID), and HFD with omega-3 fatty acids. Key outcomes assessed included body weight, serum triglycerides (TG), total cholesterol (TC), liver weight, hepatic TG levels, and epididymal fat. In cellular models, the impact of USCP119 on lipid accumulation and adipogenic markers was evaluated.
USCP119 treatment at 50 mg/kg BID resulted in the lowest weight gain (15.5%) and the most significant reductions in serum TG and hepatic TG levels compared to the HFD control. The 100 mg/kg dose also led to substantial reductions in serum TG and TC levels and notable decreases in low-density lipoprotein cholesterol. USCP119 at 50 mg/kg once daily reduced TG and TC levels but was less effective than the higher doses. In cellular models, USCP119 was non-toxic up to 400 µg/mL and effectively reduced lipid accumulation, modulated adipogenic markers, and enhanced AMPK signaling, improving lipid metabolism and insulin sensitivity.
All USCP119 treatments demonstrated effectiveness in managing hyperlipidemia and related metabolic disorders, with variations in impact depending on the dosage. The ability of USCP119 to reduce fat accumulation, improve lipid profiles, and enhance insulin sensitivity highlights its potential as a valuable dietary supplement for addressing high-fat diet-induced hyperlipidemia and metabolic disturbances.
本研究旨在探讨混合提取物（USCP119）对高脂饮食喂养的仓鼠的降血脂作用及其在体外细胞模型中的作用。
在 8 周的时间里，将高脂饮食喂养的仓鼠分为六组：正常饮食组、高脂饮食对照组、高脂饮食+50mg/kgUSCP119 组、高脂饮食+100mg/kgUSCP119 组、高脂饮食+50mg/kgUSCP119 每日两次（BID）组和高脂饮食+ω-3 脂肪酸组。评估的关键结果包括体重、血清三酰甘油（TG）、总胆固醇（TC）、肝重、肝 TG 水平和附睾脂肪。在细胞模型中，评估了 USCP119 对脂质积累和脂肪生成标志物的影响。
与高脂饮食对照组相比，USCP119 治疗 50mg/kgBID 组体重增加最少（15.5%），血清 TG 和肝 TG 水平降低最显著。100mg/kg 剂量也导致血清 TG 和 TC 水平显著降低，以及低密度脂蛋白胆固醇明显降低。USCP119 每日 50mg/kg 一次治疗可降低 TG 和 TC 水平，但效果不如高剂量。在细胞模型中，USCP119 高达 400μg/mL 时无毒性，并能有效减少脂质积累，调节脂肪生成标志物，增强 AMPK 信号转导，改善脂质代谢和胰岛素敏感性。
所有 USCP119 治疗均有效治疗高脂血症和相关代谢紊乱，剂量不同影响也不同。USCP119 降低脂肪积累、改善血脂谱和增强胰岛素敏感性的能力突出了其作为一种有价值的膳食补充剂，用于解决高脂肪饮食诱导的高脂血症和代谢紊乱的潜力。
